Clinical Significance of Circulating Tumor Cells in Hormone Receptor–positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab - Concepedia

Concepedia

Publication | Open Access

Clinical Significance of Circulating Tumor Cells in Hormone Receptor–positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab

DOI Full Paper Access

24

Citations

22

References

2020

Year

Mark Jesus M. Magbanua, Oleksandr Savenkov, Erik Asmus, Karla V. Ballman, Janet H. Scott, John W. Park, Maura N. Dickler, Ann H. Partridge, Lisa A. Carey, Eric P. Winer,

Clinical Cancer Research

Abstract

CTCs were highly prognostic for the addition of bevacizumab to first-line letrozole in patients with HR+ MBC in CALGB 40503. Further research to determine the potential predictive value of CTCs in this setting is warranted.

References

	Year	Citations

Page 1